GSK’s Emerging Market Sales Solid, Despite China Turbulence
This article was originally published in PharmAsia News
Executive Summary
While GSK's overall performance in 2014 may have been lackluster, hit by challenges to its respiratory franchise in the U.S. and flat sales in Europe, emerging markets continued to be an important source of growth. The scandal-hit China business looks set to recover this year after the turbulence of 2014.